Integrative Training Program for Pediatric Sickle Cell Pain

Eligibility Criteria

• * Provision of signed and dated informed consent form for adolescents 18 years old and caregivers' participation
• * For children \<18, informed assent and parental informed consent to participate in the study
• * Willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
• * Males and females; Ages 12-18 years for adolescents; no age limitations for caregivers
• * Documented diagnosis of sickle cell disease (any genotype) for adolescents
• * Adolescent scores at least 3 on the Pediatric Pain Screening Tool
• * Adolescent reports typical pain intensity in the past week at least 4 on a 0-10 cm Visual Analog Scale
• * Adolescent on stable disease-modifying treatments, if applicable (e.g., hydroxyurea, glutamine, voxelotor, crizanlizumab) as defined by not newly initiated or significantly increased dosages (mg/kg) in the past 3 months
• * Speak and read English
• * An adolescent has comorbid medical conditions typically associated with pain but unrelated to SCD (e.g., rheumatologic disorders or inflammatory bowel disease)
• * Adolescent has undergone genetic or hematopoietic stem cell therapy
• * Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation
• * Adolescents receiving active treatment (e.g., weekly appointments with a provider) for nonpharmacological therapies (e.g., structured behavioral pain management, physical therapy, or acupuncture program) that overlap with the active phase of the study intervention